Table 6.
Multivariate analysis to detect the relationship between clinical variables and development of VTE/AT in patients with bladder cancer and ICI
| Multivariate Analysis | |||
|---|---|---|---|
| HR | 95% CI | p value | |
| Liver metastases at initiation of ICI | 0.87 | 0.10–7.22 | 0.894 |
| Lung metastases at initiation of ICI | 1.20 | 0.22–6.39 | 0.834 |
| Bone metastases at initiation of ICI | 1.17 | 0.14–9.95 | 0.884 |
|
ECOG at initiation of ICI (cutoff > 2) |
0.99 | 0.06–16.47 | 0.990 |
|
Hemoglobin at initiation of ICI (cutoff < 10 g/dl) |
1.0 | 0.64–1.7 | 0.80 |
|
Leukocytes at initiation ICI (cutoff < 10,000 cells/mm3) |
0.49 | 0.05–5.38 | 0.562 |
|
Neutrophil/ lymphocyte ratio at initiation of ICI (cutoff < 3) |
2.26 | 0.30–16.76 | 0.426 |
|
Platelet/ lymphocyte ratio at initiation of ICI (cutoff > 300) |
0.71 | 0.10–5.10 | 0.730 |
|
Serum albumin levels (cutoff < 3.5 g/dl) |
9.21 | 1.31–64.61 | 0.02 |
|
LDH levels (cutoff > 300 U/L) |
0.61 | 0.11–3.3 | 0.570 |
|
Khorana score (cutoff > 1 point) |
1.3 | 0.26–7.3 | 0.690 |
CI confidence interval, HR hazard ratio, ICI immune checkpoint inhibitors, LDH lactate dehydrogenase